TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment TC BioPharm announces successful completion of Cohort A in the ACHIEVE clinical trial, showcasing promising results for TCB008 in treating AML.

TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial TC BioPharm celebrates a key achievement in its ACHIEVE trial by administering the initial doses to a patient in Cohort B, paving the way for innovative cancer therapies.

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment TC BioPharm provides a quarterly update on the ongoing ACHIEVE clinical trial, revealing positive safety data and plans for dose escalation of TCB008.

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008